Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

PAXGR

Neutral

Pine Tree Acquisition Corp.

Financial Services·Shell Companies

$0.20

Current Price

N/A

Market Cap

—

P/E Ratio

$0.21

52W High

$0.19

52W Low

Company Profile

CEO

N/A

Employees

N/A

Year Founded

2024

Headquarters

Albany, NY

Sector / Industry

Financial Services · Shell Companies

Key Statistics

Market Cap

N/A

Today's High

$0.21

Today's Low

$0.19

Open

$0.19

Previous Close

$0.19

52-Week High

$0.21

52-Week Low

$0.19

Today's Volume

1,903,825

Avg. Volume

N/A

Overnight Volume

N/A

Shares Outstanding

N/A

P/E Ratio

0.00

EPS

$0.00

Beta

0.00

Dividend Yield

N/A

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q3 2026N/A
Missed
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0
Rev. Actual$0
Q2 2026N/A
Missed
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0
Rev. Actual$0
Q1 2026N/A
Missed
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0
Rev. Actual$0
Q4 2025N/A
Missed
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0
Rev. Actual$0

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

Pine Tree Acquisition Corp. is a newly formed blank check company (SPAC) that recently completed its IPO in October 2026. As a SPAC, the rights (PAXGR) are speculative instruments tied to the company's ability to identify and execute a business combination. Given the lack of operational history, revenue, or earnings, the price is driven primarily by market sentiment regarding the SPAC's management team and the broader M&A environment. The current price is range-bound near its recent trading levels. A neutral stance is maintained due to the lack of fundamental catalysts until a target acquisition is announced.

7-Day Target

$0.20

+0.0%

30-Day Target

$0.21

+0.1%

6-Month Target

$0.22

+0.1%

AI Confidence

50%

Risk Level

High

Analyst Target

$2.5

Bull Case

The bull case rests on PAX-101 receiving regulatory approval for autism spectrum disorder, a market with significant unmet needs and no currently approved pharmaceutical treatments for core symptoms, potentially making it a first-in-class therapy.

Bear Case

The bear case involves the high clinical failure rate associated with neurological drug development and the company's reliance on a narrow pipeline, which poses a severe threat if current clinical trials underperform or encounter significant regulatory hurdles.

Key Catalysts

  • Top-line data readout from Phase 3 clinical trials
  • Potential orphan drug designation milestones
  • Expansion of patent portfolio and intellectual property protections
  • Positive interactions with regulatory bodies for accelerated approval paths

Key Risks

  • •High cash burn rate requiring potential dilutive financing
  • •Stringent FDA clinical and regulatory approval requirements
  • •Uncertainty regarding commercial viability and market adoption
  • •Dependence on successful Phase 3 trial outcomes

Company Overview

PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for the treatment of neurological disorders, particularly autism spectrum disorder. The company's lead candidate, PAX-101, is an intravenous formulation of suramin currently undergoing clinical trials to address core symptoms of developmental and behavioral conditions.

Want Full Access to All Research?

Unlock unlimited AI stock analysis, market signals, and daily briefings for a one-time payment of $19.99.

30-day money-back guarantee • Secure payment by Square

PAXGR Stock FAQ

What is the AI analysis for PAXGR stock?

Stockinhood's AI generates multi-timeframe price targets for PAXGR (Pine Tree Acquisition Corp.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is PAXGR stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to PAXGR based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Neutral. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for PAXGR?

The AI-generated price target for PAXGR is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $0.20. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in PAXGR?

High cash burn rate requiring potential dilutive financing Stringent FDA clinical and regulatory approval requirements Uncertainty regarding commercial viability and market adoption Dependence on successful Phase 3 trial outcomes All risk analysis is informational only and not financial advice.

What sector is PAXGR in?

Pine Tree Acquisition Corp. (PAXGR) operates in the Financial Services sector, specifically the Shell Companies industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.